1. Home
  2. RYTM vs ATHM Comparison

RYTM vs ATHM Comparison

Compare RYTM & ATHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • ATHM
  • Stock Information
  • Founded
  • RYTM 2008
  • ATHM 2008
  • Country
  • RYTM United States
  • ATHM China
  • Employees
  • RYTM N/A
  • ATHM N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • ATHM EDP Services
  • Sector
  • RYTM Health Care
  • ATHM Technology
  • Exchange
  • RYTM Nasdaq
  • ATHM Nasdaq
  • Market Cap
  • RYTM 3.8B
  • ATHM 2.9B
  • IPO Year
  • RYTM 2017
  • ATHM 2013
  • Fundamental
  • Price
  • RYTM $61.33
  • ATHM $24.51
  • Analyst Decision
  • RYTM Strong Buy
  • ATHM Hold
  • Analyst Count
  • RYTM 12
  • ATHM 3
  • Target Price
  • RYTM $76.75
  • ATHM $32.00
  • AVG Volume (30 Days)
  • RYTM 632.6K
  • ATHM 477.0K
  • Earning Date
  • RYTM 05-07-2025
  • ATHM 05-08-2025
  • Dividend Yield
  • RYTM N/A
  • ATHM 7.01%
  • EPS Growth
  • RYTM N/A
  • ATHM N/A
  • EPS
  • RYTM N/A
  • ATHM 1.80
  • Revenue
  • RYTM $136,863,000.00
  • ATHM $948,713,568.00
  • Revenue This Year
  • RYTM $37.88
  • ATHM N/A
  • Revenue Next Year
  • RYTM $72.84
  • ATHM $2.61
  • P/E Ratio
  • RYTM N/A
  • ATHM $13.64
  • Revenue Growth
  • RYTM 48.88
  • ATHM N/A
  • 52 Week Low
  • RYTM $35.35
  • ATHM $21.89
  • 52 Week High
  • RYTM $68.58
  • ATHM $34.70
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 51.78
  • ATHM 34.16
  • Support Level
  • RYTM $58.72
  • ATHM $24.36
  • Resistance Level
  • RYTM $63.24
  • ATHM $25.24
  • Average True Range (ATR)
  • RYTM 2.43
  • ATHM 0.68
  • MACD
  • RYTM -0.15
  • ATHM -0.03
  • Stochastic Oscillator
  • RYTM 65.51
  • ATHM 18.82

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About ATHM Autohome Inc.

Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead generation service provider with 30% market share, in terms of media services and lead generation revenue, in China's online auto platform media advertising market.

Share on Social Networks: